Osteoblastik Metastaz, Kan Kalsiyum ve Alkalen Fosfataz Yüksekliği Arasındaki İlişki

Abstract

Tüm vücut kemik sintigrafisi (TVKS) osteoblastik metastazların tespitinde çok sensitif, fakat non-spesifik bir tanı yöntemidir. Bu retrospektif çalışmanın amacı; kemik sintigrafisinde metastaz saptanan hastalarda, kan kalsiyum (Ca) ve total alkalen fosfatazın (AP) metastaz gösterimindeki hassasiyetini değerlendirmektir. Hasta grubu olarak osteoblastik metastaz yapan en sık üç kanser; akciğer, prostat ve meme kanseri seçilmiştir. Increased plasma calcium and alkaline phosphatase level in osteoblastic metastases The bone scan is very sensitive but not spesific for the detection of osteoblastic bone metastases. The aim of this retrospective study was to evaluate the role of plasma calcium (Ca) and alkaline phosphatase (AP) level in the detection of bone metastases of the three frequently observed cancers including the lung, prostate and breast.

Keywords

• -

References

1. Best Practice Policy Task Force from the American Urological Association. Prostate- Specific Antigen (PSA) Best Practice Policy.
2. http://www.cancernetwork.com/journals/oncology/o0002e.htm.
3. Demers LM, Costa L, Lipton A. 2000. Biochemical markers and skeletal metastases. Cancer 88, 2919-2926.
4. Erturan S, Yaman M, Aydin G, Uzel I, Müsellim B, Kaynak K. 2005. The role of whole- body bone scanning and clinical factors in detecting bone metastases in patients with non-small cell lung cancer. Chest 127, 449-454.
5. Galaski CBS. 1971. The detection of skeletal metastases from carcinoma of the breast, Surg. Gynecol. Obstet. 132, 1019-1021.
6. Hetzel M, Hetzel J, Arslandemir C, Nüssle K, Schirrmeister H., 2004.Reliability of symptoms to determine use of bone scans to identify bone metastases in lung cancer: Prospectivestudy. BMJ. 328, 1051-1052.
7. The Canadian Oncology Group. Investigating extrathoracic metastatic disease in patients with apparently operable lung cancer. 2001. Ann. Thorac. Surg. 71, 425-434.
8. Kosuda S, Yoshimura I, Aizawa T, Koizumi K, Akakura K, Kuyama J, Ichihara K, Yonese J, Koizumi M, Nakashima J, Fujii H. 2002. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer Feb PSA

9. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR. 2003. Ameri- can society of clinical oncology treatment of unresectabl non-small cell lung cancer guideline: Update
10. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC., 1993. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer JAMA. 269, 57-60
11. Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F. 2003. American College of Chest Physicians. The noninvasive staging of non small cell lung cancer: The guidelines. Chest 123, 147-156
12. Ursavas A, Karadag M, Uzaslan E, Rodoplu E, Demirdögen E, Burgazlioglu B, Gozu RO. 2007. Can clinical factors be determinants of bone metastases in non-small cell lung cancer? Ann. Thorac. Med. 2, 3-13
13. Younsi N, Montravers F, Philippe C, Seddiki M, Uzan S, Izrael V, Talbot JN. 1997. Ca 15-3 and bone scintigraphy in the follow up breast cancerInt J. Biol. Markers. 12, 154-157.
14. Ziessman HA, O’Malley JP, Thrall JH. 2006. The requisites Nuclear Medicine 3rd Ed.